Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT01662128
What this trial is testing

Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University 600
Early research (Phase 1)Active Not RecruitingNCT05293964
What this trial is testing

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 214
Early research (Phase 1)Study completedNCT00199212
What this trial is testing

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

Who this might be right for
Carcinoma Breast Stage IV
Jules Bordet Institute 19
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Post-approval studies (Phase 4)Active Not RecruitingNCT05486182
What this trial is testing

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 153
Testing effectiveness (Phase 2)Ended earlyNCT02213042
What this trial is testing

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 42
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Ended earlyNCT03501979
What this trial is testing

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Who this might be right for
Metastatic Breast CancerLeptomeningeal Disease
University of Alabama at Birmingham 17
Testing effectiveness (Phase 2)Study completedNCT02657343
What this trial is testing

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 25
Not applicableStudy completedNCT06086340
What this trial is testing

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Who this might be right for
Breast Cancer
Pfizer 779
Early research (Phase 1)Study completedNCT03281824
What this trial is testing

Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Alteogen, Inc. 27
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Large-scale testing (Phase 3)Not Yet RecruitingNCT05698186
What this trial is testing

Thero2-01S22 in HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Institut de cancérologie Strasbourg Europe 320
Not applicableStudy completedNCT06311383
What this trial is testing

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,610
Large-scale testing (Phase 3)Active Not RecruitingNCT06057610
What this trial is testing

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 868
Testing effectiveness (Phase 2)UnknownNCT05411380
What this trial is testing

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
wang shusen 73
Testing effectiveness (Phase 2)WithdrawnNCT00627627
What this trial is testing

Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
MedImmune LLC 56
Large-scale testing (Phase 3)Active Not RecruitingNCT07371910
What this trial is testing

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast CancerHRD-Positive/HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Testing effectiveness (Phase 2)Ended earlyNCT00567879
What this trial is testing

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 56
Next Page